TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005

Clinical trials for TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005 explained in plain language.

Never miss a new study

Get alerted when new TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005 trials appear

Sign up with your email to follow new studies for TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Can a new antibody calm inflammation? a First-in-Human test begins

Knowledge-focused Completed

This early-stage trial is testing whether a single dose of an experimental antibody called JS005 is safe and well-tolerated in healthy volunteers. The antibody targets IL-17A, a protein that drives inflammation, and could one day help treat inflammatory diseases. The study will a…

Matched conditions: TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005

Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Knowledge-focused

Last updated Aug 15, 2026 00:00 UTC

TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005

Get alerted when new TOLERABILITY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETIC OF JS005 trials appear

Can a new antibody calm inflammation? a First-in-Human test begins